Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Understanding Rare Adverse Outcomes Following Living Kidney Donation

Understanding Rare Adverse Outcomes Following Living Kidney Donation Opinion Editorials represent the opinions of the authors and JAMA EDITORIAL and not those of the American Medical Association. Understanding Rare Adverse Outcomes Following Living Kidney Donation John S. Gill, MD; Marcello Tonelli, MD A new era in the treatment of patients with end-stage renal sulted in unstable estimates of incidence within subgroups de- disease (ESRD) was heralded by the first successful kidney fined by age, race, sex, and patient relationship. transplant in 1954—a living donor transplant between identi- Second, the authors compared the risk of ESRD among liv- cal twins. A 23-year-old man ing donors to that among a matched subset of participants in donated his kidney to his the Third National Health and Nutrition Examination Survey brother and survived until the (NHANES III), who likely would have qualified as living do- Related article page 579 age of 79 years with a soli- nors. Although more than 96 000 living donors were included tary kidney. Today, kidney transplantation is the treatment in the study, only 9364 NHANES III participants qualified as po- of choice for patients with ESRD, and the shortage of trans- tential healthy nondonor controls. Therefore, many NHANES plantable organs is the major issue limiting the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Understanding Rare Adverse Outcomes Following Living Kidney Donation

Gill, John S.; Tonelli, Marcello
JAMA , Volume 311 (6) – Feb 12, 2014
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/understanding-rare-adverse-outcomes-following-living-kidney-donation-evJuhCtfHy

References (14)

Publisher
American Medical Association
Copyright
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2013.285142
pmid
24519296
Publisher site
See Article on Publisher Site

Abstract

Opinion Editorials represent the opinions of the authors and JAMA EDITORIAL and not those of the American Medical Association. Understanding Rare Adverse Outcomes Following Living Kidney Donation John S. Gill, MD; Marcello Tonelli, MD A new era in the treatment of patients with end-stage renal sulted in unstable estimates of incidence within subgroups de- disease (ESRD) was heralded by the first successful kidney fined by age, race, sex, and patient relationship. transplant in 1954—a living donor transplant between identi- Second, the authors compared the risk of ESRD among liv- cal twins. A 23-year-old man ing donors to that among a matched subset of participants in donated his kidney to his the Third National Health and Nutrition Examination Survey brother and survived until the (NHANES III), who likely would have qualified as living do- Related article page 579 age of 79 years with a soli- nors. Although more than 96 000 living donors were included tary kidney. Today, kidney transplantation is the treatment in the study, only 9364 NHANES III participants qualified as po- of choice for patients with ESRD, and the shortage of trans- tential healthy nondonor controls. Therefore, many NHANES plantable organs is the major issue limiting the

Journal

JAMA – American Medical Association

Published: Feb 12, 2014

There are no references for this article.